Neil F McFarlane's most recent trade in Zevra Therapeutics Inc was a trade of 61,273 Common Stock done at an average price of $7.9 . Disclosure was reported to the exchange on Feb. 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.86 per share. | 13 Feb 2025 | 61,273 | 222,060 (0%) | 0% | 7.9 | 481,428 | Common Stock |
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.05 per share. | 13 Feb 2025 | 30,544 | 191,516 (0%) | 0% | 8.1 | 245,962 | Common Stock |
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 112,500 | 112,500 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 233,333 | 283,333 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Neil F. McFarlane | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 233,333 | 466,667 | - | - | Restricted Stock Unit | |
| Collegium Pharmaceutical Inc | Neil F. McFarlane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 7,693 | 49,365 (0%) | 0% | 0 | Common Stock | |
| Zevra Therapeutics Inc | McFarlane F. Neil | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 700,000 | 700,000 | - | - | Restricted Stock Unit | |
| Collegium Pharmaceutical Inc | Neil F. McFarlane | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,792 | 41,672 (0%) | 0% | 0 | Common Stock |